Although these findings indicate that inhibition of EZH1/2 is a potential therapeutic approach for HCC, the significance of the combined use of MKIs and EZH1/2 inhibitors in HCC remains to be elucidated. The gene discussed is EZH1; the disease is hepatocellular carcinoma.